SCHEMBL2178346

SCHEMBL2178346

CCCCN(C)c1ccn(Cc2ccc(Cl)cc2Cl)c(=O)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.54
LMNA P02545 4/20 0.54
TSHR P16473 3/20 0.54
KDM4E B2RXH2 2/20 0.42
CNR1 P21554 1/20 0.41
DBH P09172 1/20 0.41
ALDH1A1 P00352 3/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
PKM P14618 2/20 0.40
CRHR1 P34998 2/20 0.39
POLB P06746 1/20 0.39
PPARG P37231 1/20 0.38
HTT P42858 3/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
CYP2D6 P10635 2/20 0.38
CYP2C19 P33261 2/20 0.38
CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2175241 0.78 TSHR (0.53) SMN1; SMN2LMNATSHRKDM4EDBH
SCHEMBL2178031 0.77 TSHR (0.52) SMN1; SMN2LMNATSHRKDM4EDBH
SCHEMBL2177416 0.74 TSHR (0.48) SMN1; SMN2LMNATSHRKDM4EDBH
SCHEMBL2175430 0.73 TSHR (0.50) SMN1; SMN2LMNATSHRKDM4EDBH
SCHEMBL2176047 0.69 SMN1; SMN2 (0.50) SMN1; SMN2LMNATSHRKDM4EDBH
SCHEMBL2175595 0.68 MAPK14 (0.43) SMN1; SMN2LMNATSHRALDH1A1
SCHEMBL2177358 0.68 LMNA (0.51) SMN1; SMN2LMNATSHRKDM4EDBH
SCHEMBL2174653 0.68 LMNA (0.51) SMN1; SMN2LMNATSHRKDM4EDBH
SCHEMBL2178830 0.68 MAPK14 (0.42) SMN1; SMN2LMNATSHRMAPK1
SCHEMBL2178004 0.68 LMNA (0.48) SMN1; SMN2LMNATSHRKDM4EDBH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070135465-A1 Fab I Inhibitor and Process for Preparing Same CRYSTALGENOMICS, INC. (KR) 2007-06-14 US claimed
US-7973060-B2 Fab I inhibitor and process for preparing same CRYSTALGENOMICS, INC. (KR) 2011-07-05 US disclosed
EP-1948601-A1 FAB I INHIBITOR AND PROCESS FOR PREPARING SAME Crystalgenomics, Inc. (KR) 2008-07-30 EP disclosed
US-20070135465-A1 Fab I Inhibitor and Process for Preparing Same CRYSTALGENOMICS, INC. (KR) 2007-06-14 US disclosed
WO-2007043835-A1 FAB I INHIBITOR AND PROCESS FOR PREPARING SAME CRYSTALGENOMICS, INC. (KR) 2007-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135465-A1 Fab I Inhibitor and Process for Preparing Same TFPI, TFPI2, FCGRT SMN1; SMN2 4359/4885LMNA 1691/4885TSHR 3182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.